CJC-1295
A modified GHRH analog that provides sustained growth hormone release, often combined with Ipamorelin.
Community Rating
No ratings yet
Compound Profile
CJC-1295
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. CJC-1295 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Sustained, elevated GH levels over extended periods
- Enhanced muscle growth and protein synthesis
- Significant fat loss, particularly visceral fat
- CJC-1295 is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Sustained, elevated GH levels over extended periods
- Enhanced muscle growth and protein synthesis
- Significant fat loss, particularly visceral fat
- Improved recovery from exercise and injury
In Plain English
Simple summaryYour brain naturally pulses growth-hormone-releasing hormone (GHRH) into your bloodstream to tell your pituitary gland to release GH -- mostly at night, mostly in short bursts. CJC-1295 is a stabilized version of that signal. It does the same job but lasts far longer than the natural hormone does. The Mod GRF 1-29 form gives you a short-acting pulse with a half-life around 30 minutes; the DAC version binds to albumin in your blood and keeps signaling for 6–8 days from a single injection. Neither form is typically used alone -- the CJC-1295 + ipamorelin pairing is what most protocols actually use, because hitting two different receptor types multiplies GH output 5–10x.
- Sustained, elevated GH levels over extended periods
- Enhanced muscle growth and protein synthesis
- Significant fat loss, particularly visceral fat
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is CJC-1295?
Tap any underlined term for an instant definition.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a significantly extended half-life compared to natural GHRH. It works by binding to the GHRH receptor in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone. The DAC (Drug Affinity Complex) version of CJC-1295 further extends its half-life to approximately 8 days by covalently binding to albumin in the bloodstream, allowing for once or twice-weekly injections. Without DAC (Mod GRF 1-29), it requires more frequent dosing but produces a more natural pulsatile GH release pattern. CJC-1295 is most commonly combined with Ipamorelin for a synergistic effect on GH release.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on CJC-1295. See all Growth Hormone Secretagogues peptides for comparison.
Common Stacks
CJC-1295 is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
The classic GH stack: CJC-1295 raises baseline GH levels while Ipamorelin delivers clean, timed pulses without cortisol or appetite spikes.
CJC-1295 provides sustained GH elevation while Tesamorelin's full-length GHRH agonism adds proven visceral fat reduction data.
CJC-1295 drives GH release which stimulates IGF-1 production; stacking with exogenous IGF-1 LR3 amplifies downstream anabolic signalling.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
CJC-1295 DAC: 1–2 mg once or twice weekly. Mod GRF 1-29 (no DAC): 100 mcg per injection, 1–3 times daily. Always combined with Ipamorelin (100–300 mcg) for optimal results. Common stacking protocol: inject both simultaneously, 30 min before bed or morning on empty stomach.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute with bacteriostatic water. For DAC version: once weekly injection is sufficient. For Mod GRF 1-29: inject simultaneously with Ipamorelin for synergistic GH pulse. Allow 2 hours of fasting before injection for maximum GH release (insulin inhibits GH). Rotate injection sites.
What the research doesn't show
Growth hormone has pro-growth signaling properties that are relevant to cancer biology at high doses. The long-term safety of sustained IGF-1 elevation from CJC-1295 DAC (which keeps signaling for days) hasn't been studied in humans. Many researchers prefer the shorter-acting Mod GRF 1-29 form specifically because it allows more control.
Research Video
Medical Expert Videos
Physicians, researchers, and pharmacologists explain CJC-1295, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
CJC-1295 has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: sustained, elevated gh levels over extended periods.
The most commonly reported side effect in research subjects is water retention and bloating. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
Research Articles
- FDA Peptide Reclassification 2026: What Researchers Need to Know10 min read
- CJC-1295: The Long-Acting GHRH Analogue Reshaping Growth Hormone Research8 min read
- Ipamorelin: What This Anti-Aging Peptide Does and Why Researchers Are Interested8 min read
- CJC-1295 Dosage Guide: Reconstitution, Injection Volume Tables, and Protocol Guide7 min read
How It Compares
Sermorelin is the older, shorter-acting GHRH analogue -- mostly used in clinical settings. Ipamorelin works at a different receptor (the ghrelin receptor) and produces a cleaner GH pulse without cortisol or prolactin spikes. The CJC-1295 + ipamorelin stack is dominant in research protocols because they're synergistic, not redundant -- they hit separate pathways simultaneously.
Compare CJC-1295 side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.